International Biotechnology

IBT offers a differentiated exposure to a secular growth theme complemented by a solid yield…

Add to watchlist Download View key data

Disclosure – Non-Independent Marketing Communication

This is a non-independent marketing communication commissioned by International Biotechnology. The report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.

International Biotechnology

International Biotechnology Trust (IBT) aims to deliver a combination of strong capital growth and consistent dividend income from investing in biotechnology companies around the world. This is a specialist area, but one that exhibits strong trends which are unlikely to be blown off track by COVID-19.

As we discuss in the Portfolio section, IBT has a unique position in the trust universe, given that it invests in both listed and unlisted companies (through a venture fund). Within the listed-equities portfolio, the team take a highly active multi-cap approach. Investee companies need to have strong pricing power, experienced management and financial strength.

Many characteristics that the managers prefer also make companies attractive targets for M&A. Within the biotechnology sector, M&A is a persistent tailwind for valuations. Since December 2017, IBT has seen 11 completed acquisitions at an average premium of 63%.

A key part of the investment philosophy is to manage risks – which is reflected in the lower NAV volatility over five years relative to the benchmark – while still showing outperformance. A key element to this is the managers’ tendency to de-risk exposures to companies in the run-up to significant drug-trial results announcements.

IBT pays a dividend of 4% of NAV each year (at the end of August) from capital. As we discuss in the Dividend section, IBT employs a growth strategy, and as such provides a very different (and potentially diversifying) underlying exposure to that provided by equity-income funds.

Analyst's View

We view the biotechnology sector as currently having attractive dynamics. As we highlight in the Performance section, the sector has underperformed wider equity markets and is at historically low P/E valuations relative to history and to the wider market.

As we discuss in the Portfolio section, the sector has secular tailwinds which make it unlikely that future prospects for companies will be dampened by COVID-19. Also, any remaining uncertainty over the US presidential election will be resolved by December. As such, the sector’s prospects look relatively bright, and this perhaps explains why the trust has performed strongly both on a relative and absolute basis so far this year.

In the current environment, where visibility on dividends everywhere is murky, we see the consistency of the dividend as a key attraction. The fact that the dividend is paid from capital means that it is not subject to the same pressures as dividends paid from current earnings. Also, the level of the dividend is attractive relative to that of other equity-income sources. For example, the AIC Global Equity Income investment-trust peer group has a historical yield of 3.8%.

IBT’s discount widened out considerably during March, but it has now narrowed back to 2.8%. The board recently made its first buybacks since September 2016, showing that it remains engaged in protecting investors from discount volatility. IBT is a differentiated proposition in a sector which should have secular tailwinds.

bull bear
Strong and specialised team, with a unique approach to biotechnology investment Biotechnology sector is inherently more volatile than wider equity indices
Offers the combination of a solid yield and good prospects for capital growth Recent history illustrates short-term discount volatility can be high
Risk-focussed investment process has seen the trust deliver outperformance of the benchmark over five years, and with lower volatility
William Heathcoat Amory
William Heathcoat Amory is a co-founding partner of Kepler Partners LLP and leads the Kepler investment trust research team. William has 18 years of experience as an investment company analyst. Prior to co-founding Kepler Partners in 2008, he was part of the Extel number 1 rated research team at JPMorgan Cazenove.

Fund History

Disclaimer

This report has been issued by Kepler Partners LLP.  The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.  

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm’s internal rules. A copy of the firm’s Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.

Welcome to Kepler Trust Intelligence

Kepler Trust Intelligence is authorised in the UK by the Financial Conduct Authority.
Please enter a valid email address
{{item.msg}}
Please enter a valid password
{{item.msg}}
Please enter a valid email address
{{item.msg}}
Please check your email. If an account exists you'll be sent instructions on how to reset your password.
Kepler Trust Intelligence is authorised in the UK by the Financial Conduct Authority. To ensure that we are able to provide content which is appropriate for you, please tell us a little about yourself.
Please choose an option
{{item.msg}}
Please enter a company name
{{item.msg}}
Please enter a location name
{{item.msg}}
Please choose an option
{{item.msg}}
Please enter a platform
{{item.msg}}
Please choose an option
{{item.msg}}
Please enter a trust
{{item.msg}}
?
The information contained herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States to or for the benefit of any United States person (being residents of the United States or partnerships or corporations organised under the laws thereof). The investment funds referred to herein have not been registered in the United States under the Investment Company Act of 1940 and units or shares of such funds are not registered in the United States under the Securities Act of 1933.
Please confirm
{{item.msg}}
Please select an option
{{item.msg}}
See benefits
A free Kepler Trust Intelligence account allows you to access premium content including the ‘Kepler View’ – our verdict on the trusts we cover – and historical research so you can see how our view has changed over time. An account also unlocks useful facilities like the ‘follow’ button which lets you keep track of the trusts you’re interested in and as a logged in user you can also download PDFs of our research, and choose the layout of the page you’re reading to suit your preference. We will not share your details unless you give us permission to do so, and we won’t bombard you with emails – we only send one a week.
Please select an option
{{item.msg}}
Please enter your first name
{{item.msg}}
Please enter your last name
{{item.msg}}
Please enter a valid email address
An account already exists with this email - have you forgotten your password?
{{item.msg}}
Please enter a valid password
{{item.msg}}
Please enter a valid password
{{item.msg}}
How will this information be used? Your answers help us to tailor our content to relevant investment trusts, and to ensure that the asset allocation and portfolio strategy research we produce is appropriate to our userbase.
Our Website uses Cookies Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies, but parts of our site won’t work without them. By using our website you accept our use of cookies. For further information please refer to the Kepler Privacy Notice.
Need help?

One more thing...

Did you know, you can 'follow' individual trusts on Kepler Trust Intelligence? Use the functions below to set up alerts and we'll send you research and updates on your chosen trusts.

Suggested trusts to follow

Browse all funds
Need help?
Current Site Kepler Trust Intelligence is produced by the investment companies team at Kepler Partners and is the UK’s premier source of detailed qualitative research on investment trusts. Absolute Hedge is a market leading UCITS research database providing proprietary research on funds, themes and strategies in the UCITS space. Kepler Liquid Strategies is a Dublin domiciled UCITS fund platform featuring a number of best-of-breed fund managers. Kepler Partners is a corporate advisory and asset raising boutique specialising in the regulated funds market in Europe and investment trusts in the UK.